openPR Logo
Press release

BioLizard Awarded EUR 300,000 VLAIO Research Grant to Establish Causal Link Between the Microbiome and Disease

08-17-2020 11:05 AM CET | Health & Medicine

Press release from: BioLizard

/ PR Agency: Halsin Partners
Supports BioLizard’s state-of-the-art bioinformatics and AI tools service offering for Pharma and Biotech to investigate microbiome-associated illnesses

Ghent, Belgium, August 17, 2020 – BioLizard, a bioinformatics and AI solutions company, today announced the receipt of a EUR 300,000 research grant from Flanders Innovation & Entrepreneurship (VLAIO) to leverage its world-leading expertise in bioinformatics, AI and machine learning, to establish the causal link between the human microbiome and disease.

The growth in researching the microbiome in academia and industry has led scientists to establish associations between microbial populations in the human gut with obesity, Parkinson’s disease, Alzheimer’s disease, COVID19 and many more health issues. This suggests that deeper understanding of the role that the microbiome plays in human health could accelerate research in drug development, biomarker discovery and nutrition.

Collecting data from the broadest set of microbes, patient background and interactions, BioLizard is building a framework using state-of-the-art bioinformatics and AI tools to evaluate causal links in the human microbiome, purely from data. This will allow evaluation of whether microbe A causes disease B or if they’re only distantly related, thereby requiring a refining of focus.

“This research grant from VLAIO will enable us to build a state-of-the-art framework to discover drug targets and biomarkers supported by real cause-effect relations as part of our bioinformatics service offering to the biopharmaceutical and nutrition industries,” said Liesbeth Ceelen, Director of Business Development at BioLizard. “From an industry perspective, these associations are extremely interesting. Since we can modulate our microbiome through nutrition, pro- and antibiotics, we should be able to influence the development of these diseases through discovery of validated targets for intervention.”

“The Flemish region is a center of excellence in bioinformatics, AI and computational biology. We are grateful to VLAIO for their recognition of start-ups in the sector and their support for future growth and entrepreneurship,” added prof. Wim Van Criekinge, co-founder of BioLizard.

BioLizard NV
Martelaarslaan 408
9000 Ghent, Belgium

Contact:

Liesbeth Ceelen
BioLizard
contact@lizard.bio

Mike Sinclair (media)
Halsin Partners msinclair@halsin.com
+44 20 7318 2955

About BioLizard

BioLizard NV leverages its expertise in bioinformatics, biostatistics, machine learning, artificial intelligence and data mining to solve the most challenging questions in biology and deliver solutions to clients. By combining expertise from diverse backgrounds, BioLizard provides a complete solution to its client - from data analysis to the system integration and the development of an AI-aided interpretation system. The company was founded by Novalis Biotech Incubation. For more information visit www.lizard.bio.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release BioLizard Awarded EUR 300,000 VLAIO Research Grant to Establish Causal Link Between the Microbiome and Disease here

News-ID: 2113610 • Views: 1136

More Releases for VLAIO

OHMX.bio and Fujirebio Europe Receive Grant of 720K EURO to Incorporate Third Ge …
Ghent, Belgium, December 8, 2020 – OHMX.bio, a provider of cutting-edge “omics” solutions, and Fujirebio Europe announced today that they have been awarded a 720K EURO research grant from Flanders Innovation & Entrepreneurship (VLAIO) to develop a clinical in vitro diagnostics (IVD) platform incorporating third generation sequencing (TGS) technologies. The project, called IVD-seq, will initially focus on a cost-efficient, accurate and portable IVD modular solution for highly polymorphic regions. The
Persomed Appoints Kristof Vercruysse as CEO to Drive Personalized Cancer Vaccine …
Ghent, Belgium, August 20, 2020 – Persomed, a consortium dedicated to the development of personalized cancer vaccines, announced today the appointment of Kristof Vercruysse as CEO. Kristof brings almost 20 years of biotech industry knowledge and business development skills to Persomed. In this new role, his contribution will be crucial for the transition of the consortium into a new company. He has been charged with the necessary strategic planning